MwanzoIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
$Â 39.78
Baada ya Saa za Kazi:(0.00%)0.00
$Â 39.78
Imefungwa: 26 Jun, 16:02:00 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$Â 40.00
Bei za siku
$Â 39.73 - $Â 40.61
Bei za mwaka
$Â 23.95 - $Â 52.34
Thamani ya kampuni katika soko
6.33B USD
Wastani wa hisa zilizouzwa
1.53M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 131.61M | 10.14% |
Matumizi ya uendeshaji wa biashara | 83.55M | 39.85% |
Mapato halisi | -146.94M | -2.90% |
Kiwango cha faida halisi | -111.64 | 6.58% |
Mapato kwa kila hisa | -0.92 | -20.52% |
EBITDA | -144.05M | 1.56% |
Asilimia ya kodi ya mapato | -0.08% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.15B | -3.00% |
Jumla ya mali | 2.81B | 1.77% |
Jumla ya dhima | 2.34B | -5.28% |
Jumla ya hisa | 475.73M | — |
hisa zilizosalia | 159.16M | — |
Uwiano wa bei na thamani | 13.38 | — |
Faida inayotokana na mali | -12.62% | — |
Faida inayotokana mtaji | -14.71% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -146.94M | -2.90% |
Pesa kutokana na shughuli | -150.78M | -0.56% |
Pesa kutokana na uwekezaji | 170.46M | 123.98% |
Pesa kutokana na ufadhili | 2.20M | -90.67% |
Mabadiliko halisi ya pesa taslimu | 22.12M | 143.90% |
Mtiririko huru wa pesa | -107.97M | -16.56% |
Kuhusu
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1989
Makao Makuu
Tovuti
Wafanyakazi
1,069
